沈阳肤康皮肤病医院专不专业评价咋样沈阳肤康皮肤病医院治疗皮肤科评价怎么样正规嘛,沈阳皮肤癣治疗需价格,沈阳 扁平疣 价钱,沈阳有哪些治疗狐臭比较好的医院,沈阳看青春痘那家做好,沈阳有治疗脱发的地方吗,沈阳狐臭的保守治疗方法

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

HONOLULU, United States, Nov. 12 (Xinhua) -- Chinese President Hu Jintao said here Saturday that China will deepen economic structural reform, grow a green economy, enhance protection of intellectual property rights and open wider to the outside world.Hu made the remarks at the CEO summit of the Asia-Pacific Economic Cooperation (APEC) ahead of the APEC Economic Leaders' Meeting.Hu noted that while China's economy has grown steadily and the country is opening wider to the outside world, China still faces the major challenge of unbalanced, uncoordinated and unsustainable development.China, he said, will continue to deepen reform and opening-up, improve people's livelihood and promote sustained, steady and fairly fast economic growth and social harmony and stability.Hu then laid out a four-point proposal to achieve the goals, with the first being that China will deepen economic structural reform and improve business and investment environment.Second, China will honor its commitment to growing a green economy and promoting the conservation culture, Hu said.From 2011 to 2015, China's investment in the environmental sector will double that of the previous five years to about 3.1 trillion yuan (about 488.5 billion U.S. dollars), Hu said, adding that China's green industry is a key area for foreign investment.Third, China will step up protection of intellectual property rights and make itself a country driven by innovation, he said.China will vigorously boost scientific and technological innovation and turn enterprises into major players of such innovation, while further improving the legal system for intellectual property rights protection, he said.Fourth, China will open wider to the outside world and take an active part in global economic governance and regional cooperation, Hu said.China, he said, will give equal importance to import and export and focus more on increasing import while maintaining a stable level of export.Noting that China's development constitutes an important force driving regional and global economic growth, Hu said that China will work together with others to create a better future for the Asia-Pacific region.

BEIJING, Dec. 30 (Xinhua) -- China will push to properly resolve the case of a Chinese skipper indicted by Japan, the Foreign Ministry said Friday.Spokesman Hong Lei said this is a common fishing case, and the Chinese embassy in Japan has dispatched officials to visit the skipper.China requests that Japan ensure the rights of the Chinese skipper, Hong said, and China is communicating closely with Japan in order to properly resolve the case.The Chinese government has been requiring fishermen to fish legally, Hong said, adding that the competent authorities have done a lot in this area, and he promised to promote the management and education of Chinese fishermen.Japanese prosecutors have indicted the captain of a Chinese fishing boat for illegally operating in Japanese waters, a local official said Friday.The Nagasaki District Public Prosecutors Office has finalized its case against Zhong Jinyin, 39, following his December 20 arrest near islands off southwest Japan, according to the official.The prosecutors have not indicated whether the skipper has admitted to the charge.

BEIJING, Nov. 20 (Xinhua) -- China on Sunday morning put two satellites into orbit from the Jiuquan Satellite Launch Center in northwest China's Gansu Province.The satellites, Chuangxin 1-03 and Shiyan Satellite 4 were launched on a Long March 2D carrier rocket at 8:15 a.m. Beijing Time, said a Xinhua photographer, who witnessed the whole process.The Chuangxin 1-03, developed by the Chinese Academy of Sciences, will be used to collect and relay water conservancy, hydrological and meteorological data and data for power supply and disaster relief from monitoring stations.The Shiyan Satellite 4 will be used for experiments on space technologies and environment probe. Developed by the Chinese Research Institute of Space Technology, it is the country's fourth technology experiment satellite.The launch was the 151th of China's Long March series of rockets. The Long March-2D is one of the derivations of Long March-2.China started development of modern carrier rockets in 1956, and Long March rockets have become the main carriers for China's satellite launching.